Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic
Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s therapeutic development strategy and drive the in-house programmes into the clinic.
Click below to read:
When health care meets tech: Panelists offer advice for building blended syndicates
Cambridge, UK and Seoul, South Korea, 10 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and LG Chem Life Sciences, the life sciences division of the South Korean LG Group, today announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders, and oncology.
AMSBIO has expanded its range of Wingless/Integrated (Wnt) recombinant proteins, stable reporter cell lines, antibodies and ELISA kits to assist researchers in the fields of developmental biology and oncology.
Cambridge, UK, December 11th 2018: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD™ - the first validated biomarker based prognostic test in inflammatory disease.
Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribution to the development of antibody phage display technology.
Sandwich, Kent, UK, December 10th 2018 - Discovery Park - and some of the businesses driving its success - will use one of the UK’s leading science events to showcase why it remains the perfect location for science companies looking to grow and collaborate. It will be attending Genesis 2018 with several of its life sciences tenants, showcasing their activities and discussing its plans for the future development of the Park.
PRINCETON, NJ – Dec. 5, 2018 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of its BaseCase Toolkits, an add-on to BaseCase Interactive which helps pharmaceutical and medical device field representatives better manage and utilize their resources for use during customer presentations.
AMSBIO introduces ALiCE® - a new high yield cell-free protein expression system.
Cell-free protein expression (CFPE) is today used by protein chemists to quickly produce small amounts of proteins when screening DNA libraries. However current technologies are limited and there is a need for higher protein expression yields.
ALiCE® is a unique eukaryotic system, which yields an unprecedented 3 mg/ml of protein in batch mode. Even prokaryotic systems, which generally can only handle easy-to-express proteins, only get at their best 1 mg/ml protein in batch mode.
PRINCETON, NJ – Nov. 28, 2018 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of version 2.3 of its Trial Simulator software to help drug developers improve clinical trial design, resulting in greater likelihood of trial success.